Navigation Links
St. Jude Study Shows Effectiveness of Peramivir in Prevention of,Mortality in Mouse Model of Avian Influenza H5N1 Virus Infection

BioCryst Says Study Confirms and Extends Evidence Seen in a Previous Study

BIRMINGHAM, Ala., May 02, 2007 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. today announced that investigators at St. Jude Children's Research Hospital, Memphis, TN, reported favorable results evaluating peramivir treatment in an animal model of influenza using a highly virulent strain of H5N1 virus (an avian influenza strain that had caused fatal human infection in Viet Nam). The study, presented on April 30, 2007 by Dr. David Boltz at the 20th International Conference on Antiviral Research, Palm Springs, CA, concluded that peramivir is an effective treatment when administered intramuscularly to control H5N1 infection in mice and that these data support the potential use of this drug to control influenza in the event of a pandemic.

The objective of the study was to achieve complete protection against lethal H5N1 influenza virus infection in the mouse model through the use of intramuscular administration of peramivir, a potent neuraminidase inhibitor with antiviral activity against strains of influenza viruses, including seasonal strains and influenza H5N1 strains from avian origins.

A survival rate of 40% to 60% was observed in mice treated with one or two injections of peramivir; however, 100% survival of mice was achieved by two injections of peramivir on the first day followed by once-daily administration for 7 days. The longer duration of peramivir treatment also prevented viral replication in the tissues of the lungs, brain and spleen of the mice at the 3, 6, and 9 day post-inoculation time points.

W. James Alexander, MD, MPH, BioCryst Senior Vice President for Clinical Operations commented, "The results of this St. Jude study, performed under the careful guidance of Drs. Elena Govorkova and Robert Webster, bolsters our confidence that peramivir may be clearly beneficial in the treatment of severe i
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:9/23/2014)... , Sept. 23, 2014  Medela announced today ... Biomedical Company (ABC), assigning Medela as the exclusive distributor ... known as the Medela Enteral Feeding Pump. Through this ... help NICU parents and healthcare professionals by offering a ... Medela Enteral Feeding Pump is integral to the delivery ...
(Date:9/23/2014)... Sept. 23, 2014 A case report and ... SynCardia temporary Total Artificial Heart into a patient with ... were reversed, along with other abnormalities. ... the SynCardia Total Artificial Heart to treat a patient ... and video in the Journal of Visualized Experiments show ...
(Date:9/23/2014)... September 23, 2014 BerGenBio ... company, today announces it has been granted a ... Award from the UK,s Wellcome Trust to develop ... novel cancer target. The Wellcome Trust ... fund especially promising, innovative new therapeutic concepts through ...
Breaking Medicine Technology:Medela Enters Exclusive Enteral Feeding Pump Agreement with Atlanta Biomedical Company 21st Use of the SynCardia Total Artificial Heart in a 17-Year-Old Congenital Heart Disease Patient at Pediatric Hospital 21st Use of the SynCardia Total Artificial Heart in a 17-Year-Old Congenital Heart Disease Patient at Pediatric Hospital 31st Use of the SynCardia Total Artificial Heart in a 17-Year-Old Congenital Heart Disease Patient at Pediatric Hospital 4BerGenBio Granted a Prestigious Wellcome Trust Seeding Drug Discovery Award 2BerGenBio Granted a Prestigious Wellcome Trust Seeding Drug Discovery Award 3
(Date:9/23/2014)... a driving force behind many chronic diseases, especially ... inflammation caused by conditions such as viral hepatitis ... options. Now, scientists at Virginia Commonwealth University Massey ... in preclinical studies that blocking the expression of ... halts the development and progression of liver cancer ...
(Date:9/23/2014)... Becker's Hospital Review has published the ... and Health Systems With Great Orthopedic Programs." , ... list have orthopedic surgery departments, programs or dedicated ... sources. Exceptional orthopedic departments include physicians who provide ... treat professional athletes. , This is the fifth ...
(Date:9/23/2014)... under the curve of oxygen desaturation" (AUC Desat ) ... oxygen levels during procedures using sedation, according to a ... The AUC Desat provides information not only whether ... depth, duration, and rate of episodes of oxygen desaturation. ... University of Cincinnati and colleagues reports on the development ...
(Date:9/23/2014)... Ind. -- Contrary to what is often assumed about ... new study from The Kinsey Institute has found that ... are sexually active as often as singles without children ... children. , The study, "Dating and Sexual Behavior Among ... was published online in the Journal of Sex ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 Kenall ... has expanded its MedMaster™ M4 product line with ... extends the M4 product line – currently available ... options – providing more flexibility when designing lighting ... MedMaster M4 Series include:, •Three sizes ...
Breaking Medicine News(10 mins):Health News:Study uncovers genetic driver of inflammation, uses it to prevent and treat liver cancer 2Health News:125 Hospitals With Great Orthopedic Programs 2Health News:125 Hospitals With Great Orthopedic Programs 3Health News:125 Hospitals With Great Orthopedic Programs 4Health News:125 Hospitals With Great Orthopedic Programs 5Health News:New measure provides more data on oxygen levels during sedation 2Health News:Kinsey study of single parents' dating, sexual activity contradicts assumptions 2Health News:Kenall Expands MedMaster™ M4 Surgical Suite Product Portfolio with New 1'×4' Option 2Health News:Kenall Expands MedMaster™ M4 Surgical Suite Product Portfolio with New 1'×4' Option 3
... Ill., Jan. 6 Baxter International,(NYSE: BAX ), ... 2008 financial results on Thursday, January 22, 2009, at 8:30 ... call, please dial,866-238-0637 (domestic) or 703-639-1156 (international). Please dial ... of the call for the operator to,connect you. , ...
... Jan. 6, 2009 AMERIGROUP Corporation (NYSE: AGP ... Annual J.P. Morgan Healthcare Conference on January 14 in San ... January 14 at 6:30 p.m. Eastern Time, can be accessed ... page. A replay will be available for 30 days, and ...
... of life improved , , TUESDAY, Jan. 6 (HealthDay News) -- ... stimulation improves both physical function and quality of life after ... stimulation (DBS) performed better than currently available drug treatments, but ... a study in the Jan. 7 issue of the ...
... Surf Sweets today announced,the introduction of its organic, natural ... country. Surf Sweets provides a natural, organic candy,option ... children. , Surf Sweets gummy ... ingredients without artificial flavors and colors. Surf Sweets ...
... 6 Karen Ignagni, President and CEO of America,s Health ... CMS today showing that health spending in the United States ... percent in 2007. According to the CMS report, private ... rate as in 2006, but much lower than the recent ...
... , ... Fla. (Vocus) January 6, 2009 -- Whether you commit to your new ... this year by bringing them in for regular check ups. Regular check ... to a loved one,s life saved and less costly medical bills for pet ...
Cached Medicine News:Health News:Deep Brain Stimulation Helps Those With Advanced Parkinson's 2Health News:Deep Brain Stimulation Helps Those With Advanced Parkinson's 3Health News:AHIP Statement on National Health Expenditure Data 2Health News:Early Detection Saves Pets 2Health News:Early Detection Saves Pets 3
... ORTHOSET Radiopaque Bone Cement ... system: a sterile,ampule containing bone ... pack, and a sterile polyethylene ... a peelable pouch. The interiors ...
Antibiotics (Gentamicin) loaded, low viscosity bone cement for syringe use with an average setting time of approx. 7-9 Min., 41.6g of powder and 16.4g of liquid....
... Featuring new technology, such as a recessed ... and lens housings, this arthroscope has superior ... by EO, Steris and steam autoclaving or ... Light post/adapters to fit ACMI, Wolf, Dyonics ...
... Passport II delivery device is the second ... C11UB. Its simple-to-use syringe technology allows one-handed ... small incision. The blue colored plunger allows ... protect the haptics during insertion. The modified ...
Medicine Products: